GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance

Clinical trials revealed limited response duration of glioblastomas to VEGF-neutralizing antibody bevacizumab. Thriving in the devascularized microenvironment occurring after antiangiogenic therapy requires tumor cell adaptation to decreased glucose, with 50% less glucose identified in bevacizumab-t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCI Insight
Main Authors: Kuang, Ruby, Jahangiri, Arman, Mascharak, Smita, Nguyen, Alan, Chandra, Ankush, Flanigan, Patrick M., Yagnik, Garima, Wagner, Jeffrey R., De Lay, Michael, Carrera, Diego, Castro, Brandyn A., Hayes, Josie, Sidorov, Maxim, Garcia, Jose Luiz Izquierdo, Eriksson, Pia, Ronen, Sabrina, Phillips, Joanna, Molinaro, Annette, Koliwad, Suneil, Aghi, Manish K.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5256137/
https://ncbi.nlm.nih.gov/pubmed/28138554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.88815
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados